Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

PAR-22-057: Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)

Closed Closed January 22, 2022 Opportunity PAR-22-057

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.

National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 22, 2022.

From the official notice on Grants.gov, last changed January 21, 2022. Checked November 7, 2026.

About this NIH notice

Application due dates, page limits and budget limits are set in the notice. Read PAR-22-057 in the NIH Guide.

Other notices with this title

National Institutes of Health has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
PAR-23-161April 19, 2023Closed July 7, 2023Closed
PAR-22-058January 21, 2022Closed April 19, 2023Closed

Key dates

PostedJanuary 6, 2022
DeadlineJanuary 22, 2022
Archived by Grants.govFebruary 21, 2022

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

All 15 applicant types the notice lists

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

This Funding Opportunity Announcement (FOA) invites applications from early and mid-career investigators (i.e. postdoctoral fellow/associates associate professor) who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of therapeutic drug, biologic, or device development. The development of novel treatments for pain, addiction, and overdose is a vital component to address the ongoing opioid epidemic. This development will be most effective if performed by scientists with training in translational science. Translation is defined as the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public from diagnostics and therapeutics to medical procedures and behavioral changes, with translational science representing the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process (https://ncats.nih.gov/translation). Traditional academic training provides deep knowledge of a relatively narrow scientific discipline. While domain expertise is an important characteristic of a proficient translational scientist, a comprehensive understanding of the stages of therapeutic development is also necessary. For many trainees, acquiring needed expertise through participatory training in the various fields that are required to compile an investigational new drug (IND), investigational device exemption (IDE), or new drug application (NDA) is extraordinarily difficult given the diversity of these domains.

Category: Education, Health.

Who has won Aging Research grants before

From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Regents of the University of California, San FranciscoCalifornia337$575 million
The Trustees of Columbia University in the City of New YorkNew York242$574 million
University of Southern CaliforniaCalifornia203$572 million
The Washington UniversityMissouri210$556 million
Regents of the University of MichiganMichigan232$538 million

Top states: California ($3.4 billion), New York ($2.0 billion), Massachusetts ($1.8 billion), Pennsylvania ($1.0 billion), Texas ($912 million).

Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before

From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The General Hospital CorporationMassachusetts203$288 million
The Regents of the University of California, San FranciscoCalifornia248$277 million
The Johns Hopkins UniversityMaryland230$276 million
The Trustees of Columbia University in the City of New YorkNew York188$226 million
Regents of the University of MichiganMichigan179$221 million

Top states: California ($1.4 billion), New York ($926 million), Massachusetts ($906 million), Pennsylvania ($626 million), Texas ($499 million).

Who has won Drug Use and Addiction Research Programs grants before

From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
Yale UnivConnecticut150$305 million
The Johns Hopkins UniversityMaryland156$262 million
University of California, San DiegoCalifornia120$242 million
University of Pittsburgh - of the Commonwealth System of Higher EducationPennsylvania100$182 million
New York UniversityNew York62$173 million

Top states: California ($1.1 billion), New York ($773 million), Massachusetts ($613 million), Pennsylvania ($488 million), Maryland ($434 million).

Other programs behind this notice

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is PAR-22-057 still open?

No. It closed on January 22, 2022.

Who can apply for Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)?

Closed January 22, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

Who has won Oral Diseases and Disorders Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.

Similar open grants